Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue affecting many cancer drugs
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology
Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells
With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors
The UCLA research team created a low cost and customizable lipid nanoparticle using “click chemistry” for precise targeting of cancer cell surface markers
Company plans to launch FDA IND enabling studies needed to apply for approval to proceed with human trials
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments